Syros Pharmaceuticals Inc (NASDAQ:SYRS) Just Reported Increased Shorts

September 30, 2018 - By Matthew Richard

The stock of Syros Pharmaceuticals Inc (NASDAQ:SYRS) registered an increase of 10.58% in short interest. SYRS’s total short interest was 1.51 million shares in September as published by FINRA. Its up 10.58% from 1.37M shares, reported previously. With 80,100 shares average volume, it will take short sellers 19 days to cover their SYRS’s short positions. The short interest to Syros Pharmaceuticals Inc’s float is 6.18%.

The stock increased 0.76% or $0.09 during the last trading session, reaching $11.91. About 54,217 shares traded. Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has declined 23.31% since September 30, 2017 and is downtrending. It has underperformed by 38.93% the S&P500.

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing treatments for cancer and immune-mediated diseases, and building a pipeline of gene control medicines. The company has market cap of $400.82 million. The Company’s lead drug candidates are SY-1425, a selective RARa agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor with potential in a range of solid tumors and blood cancers. It currently has negative earnings. The firm was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012.

More news for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) were recently published by: Bizjournals.com, which released: “Battle of the biotech bosses: Syros execs face off in ‘Lab Olympics'” on September 24, 2018. Businesswire.com‘s article titled: “Syros to Present at 2018 Cantor Global Healthcare Conference” and published on September 26, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: